- India
- /
- Life Sciences
- /
- NSEI:INNOVACAP
Innova Captab Limited (NSE:INNOVACAP) Just Released Its Full-Year Earnings: Here's What Analysts Think
Innova Captab Limited (NSE:INNOVACAP) shareholders are probably feeling a little disappointed, since its shares fell 6.2% to ₹869 in the week after its latest annual results. Results were roughly in line with estimates, with revenues of ₹13b and statutory earnings per share of ₹22.41. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the consensus forecast from Innova Captab's twin analysts is for revenues of ₹17.5b in 2026. This reflects a sizeable 39% improvement in revenue compared to the last 12 months. Per-share earnings are expected to surge 35% to ₹30.35. In the lead-up to this report, the analysts had been modelling revenues of ₹18.2b and earnings per share (EPS) of ₹32.45 in 2026. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the small dip in earnings per share expectations.
See our latest analysis for Innova Captab
The analysts made no major changes to their price target of ₹1,091, suggesting the downgrades are not expected to have a long-term impact on Innova Captab's valuation.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Innova Captab's rate of growth is expected to accelerate meaningfully, with the forecast 39% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 20% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 16% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Innova Captab to grow faster than the wider industry.
The Bottom Line
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Innova Captab. They also downgraded Innova Captab's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At least one analyst has provided forecasts out to 2028, which can be seen for free on our platform here.
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Innova Captab that you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:INNOVACAP
Innova Captab
An integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally.
Exceptional growth potential with excellent balance sheet.
Market Insights
Community Narratives


